NCT07722780尚未招募2 期
Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Clinical Trial to Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of Premature Ejaculation
Vigonvita Life Sciences1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2026年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Mean intravaginal ejaculatory latency time (IELT) over the treatment period
研究概览
简要总结
This trial adopted a multicenter, randomized, double-blind, placebo-controlled design and consisted of two parts: Part Ⅰ and Part Ⅱ.
详细描述
Part Ⅰ is a 4-week treatment period and Part Ⅱ is a 12-week treatment period, to evaluate the efficacy, safety, and PK/PD relationships of different doses of VV913 capsules in the treatment of premature ejaculation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male participants aged 18 to 55 years old (inclusive).
- •Diagnosed with premature ejaculation (PE) per the definition issued by the International Society for Sexual Medicine (ISSM).
- •Participants achieved ≥4 coital ejaculations during the run-in period, with intravaginal ejaculatory latency time (IELT) ≤ 2 min in ≥75% of all sexual intercourse attempts.
- •Participants had a Premature Ejaculation Diagnostic Tool (PEDT) total score ≥
- •Participants maintained a stable sexual relationship with the same adult female partner for a minimum of 3 months, and intended to sustain this relationship throughout the study period.
- •Participants agreed to complete ≥4 coital ejaculations every 28 days during the double-blind treatment period, and were capable of completing all study visits, examinations, assessments and other trial-related procedures as specified in the protocol.
- •Participants fully understood the study procedures, volunteered to participate in this trial, and provided written informed consent.
- •Participants must use reliable contraceptive measures from the date of informed consent signature until 3 months after the last study drug administration.
排除标准
- •Participants with known hypersensitivity to any components of VV913 capsules or its placebo, or a prior history of hypersensitivity to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).
- •Participants suffering from erectile dysfunction, defined as a total score ≤21 on the International Index of Erectile Function-5 (IIEF-5).
- •Participants who had genitourinary diseases that may impair sexual function (e.g., prostatitis, phimosis, urinary tract infection, etc.) or underwent genitourinary surgery within 28 days prior to screening and during the baseline period.
- •Participants or their female partners diagnosed with psychiatric disorders by psychiatrists, such as major depressive disorder, generalized anxiety disorder, bipolar I disorder, bipolar II disorder, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, alcohol use disorder, schizophrenia or other psychiatric disorders.
- •Participants' female partners who are pregnant, breastfeeding or planning pregnancy, or suffering from gynecological diseases or receiving relevant treatments that restrict sexual activity.
- •Participants with diseases that may affect the absorption of oral medications, such as active enteropathy, partial or complete intestinal obstruction, chronic diarrhea, etc.
- •Participants with severe cardiovascular diseases judged by investigators to potentially increase trial risks, including heart failure (NYHA Class II-IV), clinically significant conduction abnormalities (e.g., second- or third-degree atrioventricular block, sick sinus syndrome, etc.), severe or unstable coronary artery disease/ischemic heart disease, severe carotid artery stenosis, left ventricular outflow tract obstruction, etc.
- •Participants with active malignant tumors, or a medical history of malignant tumors within 5 years before screening (except completely resected and cured cutaneous squamous cell carcinoma).
- •Participants with clinically significant liver or renal function abnormalities, i.e., serum ALT and/or AST > 2 times the upper limit of normal (ULN), or serum creatinine > 1.2 times ULN.
- •Participants with uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >95 mmHg) or hypotension (systolic blood pressure <90 mmHg or diastolic blood pressure <60 mmHg).
- •Participants who previously discontinued SSRIs or SNRIs due to adverse reactions, or experienced syncope after administration of such drugs.
- •Participants who received any anti-premature ejaculation treatment within 28 days before randomization.
- •Participants who used monoamine oxidase inhibitors, strong CYP3A4 inhibitors, moderate CYP3A4 inhibitors, strong CYP3A4 inducers or moderate CYP3A4 inducers within 28 days before randomization, or required concomitant use of such agents during the trial.
- •Participants who participated in another clinical trial and received investigational medicinal products or medical device treatment within 3 months prior to screening.
- •Participants with other conditions deemed ineligible for trial participation by the investigator.
结局指标
主要结局
Mean intravaginal ejaculatory latency time (IELT) over the treatment period
时间窗: Part I: Week 4; Part II: Week 12
Assessed was the mean IELT. IELT is measured with a stopwatch during each sexual intercourse throughout treatment.
次要结局
- Mean IELT after the first dose, Week 4 and Week 8 of treatment(Part I: first dose; Part II: first dose, Week 4, Week 8)
- Changes from baseline in mean IELT after the treatment period(Part I: first dose, Week 4; Part II: first dose, Week 4, Week 8, Week 12)
- Proportion of participants with a mean IELT increase of >1 min, >2 min, and >3 min(Part I: Week 4; Part II: Week 4, Week 8, Week 12)
- Geometric mean ratio of mean IELT during the treatment period to baseline mean IELT(Part I: Week 4; Part II: Week 4, Week 8, Week 12)
- Change from baseline in Premature Ejaculation Diagnostic Tool (PEDT) score(Part I: Week 4; Part II: Week 4, Week 8, Week 12)
- Changes from baseline in the Index of Premature Ejaculation (IPE) Domains of Ejaculatory Control, Distress and Sexual Satisfaction(Part II: Week 4, Week 8, Week 12)
- Changes from baseline in Premature Ejaculation Profile (PEP)(Part II: Week 4, Week 8, Week 12)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
3 期
Octreotide Microspheres for Preventing Pancreatic FistulaNCT07479784Shanghai Zhongshan Hospital230
招募中
2 期
A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)NCT07311200InventisBio Co., Ltd120
招募中
3 期
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use DisorderCannabis WithdrawalNCT07644052PleoPharma, Inc.420
招募中
2 期
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic DermatitisAtopic DermatitisDermatitisEczemaNCT07599813Apollo Therapeutics Ltd280
招募中
2 期
A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseNCT07418736CSPC ZhongQi Pharmaceutical Technology Co., Ltd.318